Nexalin Technology Valuation
Is NXL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Book gegen Gleichaltrige
Price-To-Book gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of NXL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von NXL für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von NXL für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NXL?
Other financial metrics that can be useful for relative valuation.
What is NXL's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$17.85m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 134.6x |
Enterprise Value/EBITDA | -2.6x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does NXL's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.5x | ||
INBS Intelligent Bio Solutions | 3.3x | 65.8% | US$10.8m |
POAI Predictive Oncology | 1x | n/a | US$8.0m |
SONX Sonendo | 0.2x | 40.6% | US$7.1m |
SSKN STRATA Skin Sciences | 1.4x | 35.4% | US$15.4m |
NXL Nexalin Technology | 5x | n/a | US$17.8m |
Price-To-Book gegen Gleichaltrige: NXL ist auf der Grundlage des Price-To-Sales Verhältnisses (23.4x) im Vergleich zum Durchschnitt der Vergleichsgruppe (2.5x) teuer.
Price to Earnings Ratio vs Industry
How does NXL's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Book gegen Industrie: NXL ist teuer, wenn man sein Price-To-Sales Verhältnis (23.4x) mit dem US Medical Equipment Branchendurchschnitt (3.2x) vergleicht.
Price to Book Ratio vs Fair Ratio
What is NXL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 5x |
Fair PB Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Sales Fair Ratio von NXL für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.